

MERRIMACK PHARMACEUTICALS INC  
Form 8-K  
October 14, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**  
**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 13, 2016

**Merrimack Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in its Charter)

<b>Delaware</b> <b>(State or Other Jurisdiction</b>	<b>001-35409</b> <b>(Commission</b>	<b>04-3210530</b> <b>(IRS Employer</b>
<b>of Incorporation</b>	<b>File Number)</b>	<b>Identification No.)</b>

**One Kendall Square, Suite B7201**

<b>Cambridge, MA</b> <b>(Address of Principal Executive Offices)</b>	<b>02139</b> <b>(Zip Code)</b>
Registrant's telephone number, including area code: (617) 441-1000	

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 13, 2016, the Board of Directors of Merrimack Pharmaceuticals, Inc. (the Company ) approved the payment to Gary Crocker, the Company s interim President and Chief Executive Officer, of a base salary equal to \$5,000 per week, retroactive to October 3, 2016 when he assumed such positions.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MERRIMACK PHARMACEUTICALS, INC.**

Date: October 14, 2016

By: /s/ Jeffrey A. Munsie  
Jeffrey A. Munsie

General Counsel